Clinical study of tauro ursodeoxycholic acid on the relapse of cholecystolithiasis after gallbladder-protected lithotomy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001932

Enrollment

Unknown

Registered

2011-12-29

Start date

2010-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cholecystolithiasis

Interventions

1:250 mg tauro ursodeoxycholic acid

2:250 mg tauro ursodeoxycholic acid

3:750 mg tauro ursodeoxycholic

4:Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. cholecystolithiasis patient; 2. ages 20 to 70 years old; 3. B ultrasonic showe that gallbladder systolic function is good; 4. B ultrasonic shows the gallbladder wall thickness less than 4 mm.

Exclusion criteria

Exclusion criteria: 1. history of Operation on abdominal region; 2. complicating acute cholecystitis, pancreatitis, calculus of common bile duct, obstruction of common bile duct; 3. with severe liver?heart and lung disease, obstacles of clotting mechanism, tuberculosis active period; 4. duration of pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame
relapse of cholecystolithiasi;	—

Secondary

Measure	Time frame
cholesterol in bile;bile acid;phospholipins in bile;gallbladder systolic function;gallbladder wall thicknes;	—

Countries

China

Contacts

Public ContactTian Fuzhou,Chen Liguo

tfz30061@yahoo.com.cn+86 13018235358

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026